The APG5L antibody, also known as anti-ATG5 antibody, targets the autophagy-related protein 5 (ATG5), a critical component of the autophagy pathway. Autophagy is a conserved cellular process that degrades and recycles cytoplasmic components via lysosomal machinery, maintaining cellular homeostasis. ATG5 plays a central role in autophagosome formation by conjugating with ATG12 to form the ATG12-ATG5 complex, which facilitates the elongation and closure of autophagosomal membranes. This complex also interacts with microtubule-associated protein 1 light chain 3 (LC3), promoting LC3 lipidation—a key step in autophagy progression.
APG5L antibodies are widely used in research to detect ATG5 expression, monitor autophagy activity, and study its dysregulation in diseases. In cancer, autophagy can act as both a tumor suppressor and a survival mechanism, making ATG5 a biomarker for therapeutic response. In neurodegenerative disorders like Alzheimer’s, impaired autophagy contributes to protein aggregate accumulation. APG5L antibodies also help explore infections, as pathogens often manipulate autophagy for survival.
Available in various formats (e.g., monoclonal, polyclonal), these antibodies are validated for techniques like Western blot, immunofluorescence, and flow cytometry. Their specificity and sensitivity make them essential tools for elucidating autophagy mechanisms and developing targeted therapies.